Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2
Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/5/1061 |
| _version_ | 1827670204850634752 |
|---|---|
| author | Julia Solek Jedrzej Chrzanowski Adrianna Cieslak Aleksandra Zielinska Dominika Piasecka Marcin Braun Rafal Sadej Hanna M. Romanska |
| author_facet | Julia Solek Jedrzej Chrzanowski Adrianna Cieslak Aleksandra Zielinska Dominika Piasecka Marcin Braun Rafal Sadej Hanna M. Romanska |
| author_sort | Julia Solek |
| collection | DOAJ |
| description | Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data on immune cell composition in DCIS in relation to the clinicopathological features and molecular subtype of the lesion. We discuss the value of infiltration by various types of immune cells and the PD-1/PD-L1 axis as potential markers of the risk of recurrence. Analysis of the literature available in PubMed and Medline databases overwhelmingly supports an association between densities of infiltrating immune cells, traits of immune exhaustion, the foci of microinvasion, and overexpression of HER2. Moreover, in several studies, the density of immune infiltration was found to be predictive of local recurrence as either in situ or invasive cancer in HER2-positive or ER-negative DCIS. In light of the recently reported first randomized DCIS trial, relating recurrence risk with overexpression of HER2, we also include a closing paragraph compiling the latest mechanistic data on a functional link between HER2 and the density/composition of TIME in relation to its potential value in the prognostication of the risk of recurrence. |
| first_indexed | 2024-03-10T03:17:47Z |
| format | Article |
| id | doaj.art-c18711d991814bdb9631bdf4d3192824 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T03:17:47Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-c18711d991814bdb9631bdf4d31928242023-11-23T10:10:28ZengMDPI AGBiomedicines2227-90592022-05-01105106110.3390/biomedicines10051061Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2Julia Solek0Jedrzej Chrzanowski1Adrianna Cieslak2Aleksandra Zielinska3Dominika Piasecka4Marcin Braun5Rafal Sadej6Hanna M. Romanska7Department of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, PolandDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 90-419 Lodz, PolandDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 90-419 Lodz, PolandDepartment of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, PolandDepartment of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-210 Gdansk, PolandDepartment of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, PolandDepartment of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-210 Gdansk, PolandDepartment of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, PolandIncreasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data on immune cell composition in DCIS in relation to the clinicopathological features and molecular subtype of the lesion. We discuss the value of infiltration by various types of immune cells and the PD-1/PD-L1 axis as potential markers of the risk of recurrence. Analysis of the literature available in PubMed and Medline databases overwhelmingly supports an association between densities of infiltrating immune cells, traits of immune exhaustion, the foci of microinvasion, and overexpression of HER2. Moreover, in several studies, the density of immune infiltration was found to be predictive of local recurrence as either in situ or invasive cancer in HER2-positive or ER-negative DCIS. In light of the recently reported first randomized DCIS trial, relating recurrence risk with overexpression of HER2, we also include a closing paragraph compiling the latest mechanistic data on a functional link between HER2 and the density/composition of TIME in relation to its potential value in the prognostication of the risk of recurrence.https://www.mdpi.com/2227-9059/10/5/1061DCISrecurrencetumour immune microenvironmentHER2 |
| spellingShingle | Julia Solek Jedrzej Chrzanowski Adrianna Cieslak Aleksandra Zielinska Dominika Piasecka Marcin Braun Rafal Sadej Hanna M. Romanska Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2 Biomedicines DCIS recurrence tumour immune microenvironment HER2 |
| title | Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2 |
| title_full | Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2 |
| title_fullStr | Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2 |
| title_full_unstemmed | Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2 |
| title_short | Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2 |
| title_sort | subtype specific tumour immune microenvironment in risk of recurrence of ductal carcinoma in situ prognostic value of her2 |
| topic | DCIS recurrence tumour immune microenvironment HER2 |
| url | https://www.mdpi.com/2227-9059/10/5/1061 |
| work_keys_str_mv | AT juliasolek subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2 AT jedrzejchrzanowski subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2 AT adriannacieslak subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2 AT aleksandrazielinska subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2 AT dominikapiasecka subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2 AT marcinbraun subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2 AT rafalsadej subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2 AT hannamromanska subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2 |